REG - BiVictriX Therapcts. - Publication of Annual Report and Notice of AGM

Bivictrix TherapeuticsAnnouncement

09/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI0976Ea&default-theme=true

RNS Number : 0976E  BiVictriX Therapeutics PLC  09 March 2022

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company" or "the Group")

 

Publication of Annual Report and Notice of AGM

 

Alderley Park, 9 March 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces that its annual report and financial statements
for the year ended 31 December 2021 ("Annual Report and Accounts") are
available for download on the Company's website at
 https://www.bivictrix.com/investor-centre
(https://www.bivictrix.com/investor-centre) ; and confirms the date for its
Annual General Meeting ("AGM").

 

The Annual Report and Accounts will be mailed to shareholders, who have
elected to opt out on receiving electronic communications, later today.

 

The Company will hold its AGM on Thursday, 31 March 2022 at 12:00pm GMT at the
Company' registered office, Mereside Alderley Park, Alderley Edge, Manchester,
SK10 4TG.

 

-Ends-

 

 

For more information, please contact:

 BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                                 Email: info@bivictrix.com

 SP Angel Corporate Finance LLP (NOMAD and Broker)                   Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Consilium Strategic Communications
 Mary-Jane Elliott, Melissa Gardiner, Genevieve Wilson, Alex Gunter  Tel: +44 (0) 20 3709 5700

                                                                     Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of solid tumour and haematological cancer
indications. The Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRGDXBUGDGDI